1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Karyopharm Therapeutics Inc (KPTI)
  7. Quote


Karyopharm Therapeutics Stock Price

-0.74 (-10.16%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,846,101
Bid Price 6.67
Ask Price 6.74
News (1)
Day High 7.29


52 Week Range


Day Low 6.66
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Karyopharm Therapeutics Inc KPTI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.74 -10.16% 6.54 19:49:23
Open Price Low Price High Price Close Price Prev Close
7.29 6.66 7.29 6.72 7.28
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13,992 1,846,101 $ 6.95 $ 12,837,808 - 4.41 - 18.00
Last Trade Time Type Quantity Stock Price Currency
19:49:44 10 $ 6.74 USD


Draw Mode:

Karyopharm Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 494.08M 75.55M 71.79M $ 108.09M $ - -2.72 -2.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 3.30%

more financials information »

Karyopharm Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KPTI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.517.666.6056.991,793,569-0.97-12.92%
1 Month7.978.706.6057.821,722,000-1.43-17.94%
3 Months5.758.705.147.001,830,7220.7913.74%
6 Months9.2611.184.417.311,654,437-2.72-29.37%
1 Year17.4318.004.4110.852,011,049-10.89-62.48%
3 Years11.5429.613.8012.341,714,208-5.00-43.33%
5 Years9.2629.613.8012.551,194,480-2.72-29.37%

Karyopharm Therapeutics Description

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.